homepage-top-section

An international team led by researchers at the US National Institutes of Health (NIH) and the University of North Carolina at Chapel Hill have found that SARS-CoV-2 virus

A study led by the University of California, Los Angeles (UCLA) has identified a compound, berzosertib, which showed potential in treating SARS-CoV-2 virus which causes Covid-19. The study

Italian pharmaceutical company Fidia Farmaceutici has signed a binding agreement to acquire an integrated portfolio of anti-inflammatory drugs from Sanofi. Under the terms of the agreement, Fidia will

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines. Dyadic’s

Johnson & Johnson’s Janssen Pharmaceutical Companies have announced the US Food and Drug Administration (FDA) approval of PONVORY for the treatment of relapsing forms of multiple sclerosis (MS)

The US-based clinical stage biopharmaceutical company Boston Pharmaceuticals has announced the signing of a unique three-year out-license and option agreement with the UK-based GlaxoSmithKline (GSK). With this agreement,

The US Food and Drug Administration (FDA) has extended the review period for AbbVie’s supplemental New Drug Application (sNDA) for upadacitinib. The global R&D-based biopharmaceutical company’s new drug

The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan. A candidate from

California-based biopharmaceutical company Gilead Sciences, Inc. and New Jersey-based Merck have announced their agreement to develop and commercialise the long-acting HIV treatments lenacapavir and islatravir. The treatments combine